CP-283-097

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameCP-283-097

Drug Alias NameCP-283,097CP-283 097CP-283097

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists

TargetsGlutamate [NMDA] receptor subunit epsilon 2

Therapy Area/IndicationsNervous System Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsNervous System Diseases

ATC CodeN/A